According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Findings demonstrate ATYR2810's anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

Abstract 1679, under the session ‘Drug Combination Strategies for Cancer Treatment’, showed that APG-2449, a novel focal ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American ...